Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

Immunotherapy plus chemotherapy versus chemotherapy alone in metastatic non–small-cell lung cancer: A systematic review with meta-analysis.. JCO 37 , e20700-e20700 (2019). DOI: ...

It's entitled "Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with a ...

Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis of randomized controlled trials. Isadora Mamede ...

Yet immunotherapy has faced some prominent setbacks. In August a clinical trial of the Bristol-Myers Squibb drug Opdivo, or nivolumab, for a group of patients with newly diagnosed lung cancer ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

In the MMR-proficient cohort, median PFS reached 11.1 months with the addition of pembrolizumab versus 8.5 months with chemotherapy alone (HR 0.60, 95% CI 0.46-0.78, P<0.0001).

SAN ANTONIO — An immunotherapy-chemotherapy combination conferred benefit for certain patients with high-risk breast cancer, ... (10.2% vs. 8.1%), denoting less residual cancer burden.

Combining immunotherapy with chemotherapy may improve survival in extensive-stage small cell lung cancer without increasing treatment-related toxicity. The study showed a median overall survival ...

The combination of durvalumab with chemotherapy, versus chemotherapy alone, in conjunction with in-depth genomic characterization of biospecimens from patients with mesothelioma, is being further ...

Tecentriq plus chemotherapy reduced recurrence or death risk by 50% in stage III colorectal cancer with deficient mismatch repair. The combination therapy achieved a 3-year disease-free survival rate ...

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had ...